Back to today’s briefing

Story perspectives

Vertex Pharmaceuticals Halts VX-993 Amid Trial Setback

8/5/2025

24 2

Summary

Story summary

Vertex Pharmaceuticals faced a setback as its non-opioid pain drug VX-993 failed to outperform a placebo in a Phase 2 trial. While the company has decided to halt its pursuit for acute pain treatment, hope remains alive as they continue testing for chronic nerve pain in diabetic patients, as confirmed by CEO Reshma Kewalramani.

1 of 1

Story summary

Vertex Pharmaceuticals faced a setback as its non-opioid pain drug VX-993 failed to outperform a placebo in a Phase 2 trial. While the company has decided to halt its pursuit for acute pain treatment, hope remains alive as they continue testing for chronic nerve pain in diabetic patients, as confirmed by CEO Reshma Kewalramani.